scholarly journals Is an elevated hemoglobin concentration a novel risk factor for metabolic syndrome in the Chinese population? a large-scale study

Oncotarget ◽  
2016 ◽  
Vol 0 (0) ◽  
Author(s):  
Xiao-Dong Zhou ◽  
Sheng-Jie Wu ◽  
Li-Ren Wang ◽  
Wen-Yue Liu ◽  
Ji-Na Zheng ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Chinese Population ◽  
Large Scale ◽  
Hemoglobin Concentration ◽  
Large Scale Study

The association between hematological parameters and metabolic syndrome in Iranian men: A single center large-scale study

2018 ◽  
Vol 12 (1) ◽  
pp. 17-21 ◽  
Author(s):  
Jamal Ahmadzadeh ◽  
Behnam Mansorian ◽  
Mohammad Mirza-Aghazadeh Attari ◽  
Ira Mohebbi ◽  
Raha Naz-Avar ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Large Scale ◽  
Hematological Parameters ◽  
Single Center ◽  
Large Scale Study

scholarly journals Evaluating Mobile Apps and Biosensing Devices to Monitor Physical Activity and Respiratory Function in Smokers With and Without Respiratory Symptoms or Chronic Obstructive Pulmonary Disease: Protocol for a Proof-of-Concept, Open-Label, Feasibility Study (Preprint)

2019 ◽  
Author(s):  
Almaz Sharman ◽  
Baurzhan Zhussupov ◽  
Dana Sharman ◽  
Irina Kim
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Metabolic Syndrome ◽  
Heart Rate ◽  
Pulmonary Disease ◽  
Chronic Diseases ◽  
Large Scale ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Treatment Assessment ◽  
Large Scale Study

BACKGROUND Chronic obstructive pulmonary disease (COPD) is a global public health problem, and continuous monitoring is essential for both its management as well as the management of other chronic diseases. Telemonitoring using mobile health (mHealth) devices has the potential to promote self-management, improve control, increase quality of life, and prevent hospital admissions. OBJECTIVE This study aims to demonstrate whether a large-scale study assessing the use of mHealth devices to improve the treatment, assessment, compliance, and outcomes of chronic diseases, particularly COPD and cardio-metabolic syndrome, is feasible. This will allow our team to select the appropriate design and characteristics for our large-scale study. METHODS A total of 3 cohorts, with 9 participants in each, will use mHealth devices for 90 days while undergoing the current standard of care. These groups are: 9 “non-COPD,” otherwise healthy, smokers; 9 “grey zone” smokers (forced expiratory volume in 1 second/ forced vital capacity ≥0.70 after bronchodilator treatment; COPD Assessment Test ≥10); and 9 smokers diagnosed with Stage 1-3 COPD. Rates of recruitment, retention, and adherence will be measured. Overall, two mHealth devices will be utilized in the study: the AnaMed Original Equipment Manufacturer device (measures distance, energy expenditure, heart rate, and heart rate variability) and the Air Next mobile spirometry device. The mHealth devices will be compared against industry standards. Additionally, a questionnaire will be administered to assess the participants’ perceptions of the mHealth technologies used. RESULTS The inclusion of participants started in June 2019. Study results will be published in peer-reviewed scientific journals. CONCLUSIONS This study will demonstrate whether a large-scale study to assess the use of mHealth devices to improve the treatment, assessment, compliance, and outcomes of chronic diseases, particularly COPD and cardio-metabolic syndrome, is feasible. It will also allow the research team to select the appropriate design and characteristics for the large-scale study. CLINICALTRIAL ClinicalTrials.gov NCT04081961; https://clinicaltrials.gov/ct2/show/NCT04081961 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/16461

Hemoglobin concentration and incident metabolic syndrome: a population-based large-scale cohort study

Endocrine ◽  
2015 ◽  
Vol 50 (2) ◽  
pp. 390-396 ◽  
Author(s):  
Yoshitaka Hashimoto ◽  
Muhei Tanaka ◽  
Toshihiro Kimura ◽  
Noriyuki Kitagawa ◽  
Masahide Hamaguchi ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Cohort Study ◽  
Large Scale ◽  
Hemoglobin Concentration ◽  
Population Based

scholarly journals Evaluating Mobile Apps and Biosensing Devices to Monitor Physical Activity and Respiratory Function in Smokers With and Without Respiratory Symptoms or Chronic Obstructive Pulmonary Disease: Protocol for a Proof-of-Concept, Open-Label, Feasibility Study

10.2196/16461 ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. e16461 ◽  
Author(s):  
Almaz Sharman ◽  
Baurzhan Zhussupov ◽  
Dana Sharman ◽  
Irina Kim
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Metabolic Syndrome ◽  
Heart Rate ◽  
Pulmonary Disease ◽  
Chronic Diseases ◽  
Large Scale ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Treatment Assessment ◽  
Large Scale Study

Background Chronic obstructive pulmonary disease (COPD) is a global public health problem, and continuous monitoring is essential for both its management as well as the management of other chronic diseases. Telemonitoring using mobile health (mHealth) devices has the potential to promote self-management, improve control, increase quality of life, and prevent hospital admissions. Objective This study aims to demonstrate whether a large-scale study assessing the use of mHealth devices to improve the treatment, assessment, compliance, and outcomes of chronic diseases, particularly COPD and cardio-metabolic syndrome, is feasible. This will allow our team to select the appropriate design and characteristics for our large-scale study. Methods A total of 3 cohorts, with 9 participants in each, will use mHealth devices for 90 days while undergoing the current standard of care. These groups are: 9 “non-COPD,” otherwise healthy, smokers; 9 “grey zone” smokers (forced expiratory volume in 1 second/ forced vital capacity ≥0.70 after bronchodilator treatment; COPD Assessment Test ≥10); and 9 smokers diagnosed with Stage 1-3 COPD. Rates of recruitment, retention, and adherence will be measured. Overall, two mHealth devices will be utilized in the study: the AnaMed Original Equipment Manufacturer device (measures distance, energy expenditure, heart rate, and heart rate variability) and the Air Next mobile spirometry device. The mHealth devices will be compared against industry standards. Additionally, a questionnaire will be administered to assess the participants’ perceptions of the mHealth technologies used. Results The inclusion of participants started in June 2019. Study results will be published in peer-reviewed scientific journals. Conclusions This study will demonstrate whether a large-scale study to assess the use of mHealth devices to improve the treatment, assessment, compliance, and outcomes of chronic diseases, particularly COPD and cardio-metabolic syndrome, is feasible. It will also allow the research team to select the appropriate design and characteristics for the large-scale study. Trial Registration ClinicalTrials.gov NCT04081961; https://clinicaltrials.gov/ct2/show/NCT04081961 International Registered Report Identifier (IRRID) DERR1-10.2196/16461

Platelet to lymphocyte ratio as a novel indicator of inflammation is correlated with the severity of metabolic syndrome: A single center large-scale study

Platelets ◽  
2015 ◽  
Vol 27 (2) ◽  
pp. 178-183 ◽  
Author(s):  
Mehmet Kadri Akboga ◽  
Ugur Canpolat ◽  
Murat Yuksel ◽  
Cagri Yayla ◽  
Samet Yilmaz ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Large Scale ◽  
Single Center ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Large Scale Study

scholarly journals Relationship between metabolic syndrome and its components and cardiovascular disease in middle-aged and elderly Chinese population: a national cross-sectional survey

BMJ Open ◽  
2019 ◽  
Vol 9 (8) ◽  
pp. e027545 ◽  
Author(s):  
Wenzhen Li ◽  
Fujian Song ◽  
Xiaojun Wang ◽  
Dongming Wang ◽  
Dajie Chen ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Chinese Population ◽  
Large Scale ◽  
International Diabetes Federation ◽  
Density Lipoprotein ◽  
Heart Association ◽  
Population Based ◽  
Cross Sectional Survey ◽  
Cross Sectional

ObjectivesTo assess the relationship between metabolic syndrome (MetS) and its components and cardiovascular disease (CVD) according to different criteria of MetS, as well as whether the estimated association between MetS and CVD was affected by different definitions of MetS among the Chinese population.DesignPopulation-based, cross-sectional study.SettingData were from a large-scale national stroke screening survey, China National Stroke Screening and Prevention Project.ParticipantsA nationally representative sample of 109 551 Chinese adults aged ≥40 years in 2014–2015 were included.Primary outcome measuresCVD conditions (stroke, coronary heart disease (CHD) and atrial fibrillation (AF)) diagnosed by clinicians were self-reported.ResultsORs after adjusting for CHD, stroke, AF and CVD in those with MetS using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criterion were 1.56 (95% CI 1.48 to 1.63), 1.23 (95% CI 1.17 to 1.30), 1.14 (95% CI 1.08 to 1.21) and 1.40 (95% CI 1.35 to 1.45); 1.51 (95% CI 1.44 to 1.58), 1.20 (95% CI 1.14 to 1.26), 1.09 (95% CI 1.04 to 1.15) and 1.34 (95% CI 1.29 to 1.38) with the American Heart Association/National Heart, Lung, and Blood Institute criterion; and 1.41 (95% CI 1.35 to 1.48), 1.24 (95% CI 1.19 to 1.30), 1.12 (95% CI 1.06 to 1.18) and 1.31 (95% CI 1.27 to 1.35) with the International Diabetes Federation criterion, respectively. Elevated blood pressures were all highly related to the prevalence of stroke and AF, and reduced high-density lipoprotein-cholesterol was associated with a higher OR for CHD than other individual components of MetS.ConclusionsMetS is significantly associated with CVD, and the prevalence of CVD was more evident when MetS was defined according to the NCEP ATP III criterion. Developing effective public health strategies for the prevention, detection and treatment of MetS should be an urgent priority to reduce the burden of CVD in China.

Sign in / Sign up

Export Citation Format

Share Document